

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. DO NOT EXCEED FIVE PAGES.

NAME: Michele Tagliati, MD

eRA COMMONS USER NAME (credential, e.g., agency login): MTAGLIATI

POSITION TITLE: Director of Movement Disorders, Professor of Neurology, Cedars-Sinai Medical Center

EDUCATION/TRAINING

University of Rome "La Sapienza", Italy	M.D.	1980-86	Medicine
University of Rome "Tor Vergata", Italy		1987-90	Neurology (Residency)
The Mount Sinai Medical Center, New York, NY		1995-96	Medicine (Internship)
The Mount Sinai Medical Center, New York, NY		1996-99	Neurology (U.S. Residency)
Beth Israel Hospital, New York, NY		1999-00	Movement Disorders (Fellowship)

A. PERSONAL STATEMENT

Dr. Tagliati is currently Director of the Movement Disorders Program at Cedars-Sinai Medical Center. His research interests include the study of early and advanced therapeutics of Parkinson's disease, dystonia and other movement disorders. He pioneered the use of DBS in PD and dystonia. Dr. Tagliati's research contributed recognized advances in the definition of outcome predictors and therapeutic settings of DBS. Dr. Tagliati is a diplomate of the American Board of Psychiatry and Neurology, a Fellow of the American Academy of Neurology and an active member of the Movement Disorders Society. He has published over 80 peer-reviewed articles and over 25 book chapters.

B. POSITIONS AND HONORS**Positions and employment**

1987-88	Medical Officer, Italian Army
1988-90	Resident in Neurology, University of Rome "Tor Vergata", Italy
1990-91	Research Fellow in Neurophysiology, University of Rome "Tor Vergata", Italy
1991-92	Visiting Assistant Professor, VEP laboratory, Mount Sinai School of Medicine, New York, NY
1995-96	Intern, Department of Medicine, Mount Sinai Medical Center, New York, NY
1996-99	Resident in Neurology, The Mount Sinai Medical Center, New York, NY
1999-00	Clinical Fellow in Movement Disorders, Beth Israel Hospital, New York, NY
2000-04	Assistant Professor of Neurology, Albert Einstein College of Medicine
2004-10	Associate Professor of Neurology, Mount Sinai School of Medicine, New York, NY
2004-10	Chief, Movement Disorders Division, Mount Sinai School of Medicine, New York, NY
2010-	Vice Chairman, Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA,
2010-	Director, Movement Disorders, Cedars-Sinai Medical Center, Los Angeles, CA,
2011-	Professor of Neurology, Cedars-Sinai Professorial Series, Los Angeles, CA

Other experience and professional membership

1994-	Member, American Academy of Neurology
2000-	Member, Movement Disorders Society
2003-09	Member, CME Committee, Movement Disorders Society
2006-09	Scientific Advisory Board, Bachmann-Strauss Dystonia & Parkinson Research Foundation
2007-	Scientific Advisor, Parkinson Alliance
2007-10	DBS Working Group, National Parkinson Foundation
2008-09	Task Force for DBS in Dystonia, Movement Disorder Society

- 2008- Annual Meeting Planning Committee, Parkinson Study Group
- 2011-13 Pan American Section Education Committee, Movement Disorder Society,
- 2012- DSMB - ADvance: (DBS-f in patients with Alzheimer's disease)
- 2013- Medical and Scientific Advisory Council, Dystonia Medical Research Foundation
- 2013 Ad-Hoc Reviewer, Foundation for Dystonia Research
- 2014 Ad-Hoc Reviewer, NIH Bioengineering of Neuroscience, Vision & Low Vision Technologies Study Section
- 2014 Member, AAN Movement Disorders Topic Work Group, 2014-present

Honors

- 1986 Magna cum laude, University of Rome, Italy
- 1990 CNR-NATO Advanced Fellowship for Research abroad
- 1998 Chief Resident in Neurology, Mount Sinai Medical Center, NY
- 1998 American Academy of Neurology Resident Award
- 2000 Singer/Hellman Research Award
- 2005 President's Award, Dystonia Medical Research Foundation
- 2008 DMRF Dystonia Circle of Friends Award
- 2010 Fellow, American Academy of Neurology
- 2013 APDA Tribute for Exceptional Achievement
- 2015 Steven D. Broidy Endowed Chair in Movement Disorders

C. CONTRIBUTIONS TO SCIENCE

1. Studied retinal dopaminergic mechanisms *in vivo*, testing animal and human models of dopaminergic blockade in addition to patients with Parkinson's disease. Using visual evoked potentials, we demonstrated that normal spatial frequency tuning, as measured by the pattern electroretinogram, is dependent on normal dopaminergic function and could be used as a marker of Parkinson's disease. I either performed or directly supervised all of the work described below.

- a) Stanzione P, **Tagliati M**, Silvestrini M, Porcu S and Bernardi G. Haloperidol delays pattern electroretinograms more than VEPs in normal humans. *Clin Vision Sci* 1991;6:137-147.
- b) **Tagliati M**, Bodis-Wollner I, Kovanecz I, Stanzione P. Spatial frequency tuning in the monkey retina depends on D2 receptor-linked action of dopamine. *Vision Res* 1994;34:2051-2057.
- c) **Tagliati M.**, Bodis-Wollner I, Yahr M. The pattern electroretinogram in Parkinson's Disease reveals lack of retinal spatial tuning. *Electroenceph clin Neurophysiol* 1996;100:1-11.

2. Developed new patterns of stimulation and clinical outcome predictors of response to DBS in patients with primary dystonia, reporting for the first time the use of low frequencies of stimulation and that duration of disease is inversely correlated with outcome after surgery. Later studies showed that age may also have a role in determining the time course of the response to DBS in patients with dystonia. In addition, using clinical data and computerized models of volume of tissue activation by DBS, we created a probabilistic atlas of the area most frequently associated with favorable outcomes in patients with dystonia. I either performed or directly supervised all of the work described below.

- a) Alterman RL, Miravite J, Weisz D, Shils JL, Bressman S and **Tagliati M**. Sixty Hertz Pallidal DBS for Primary Torsion Dystonia. *Neurology* 2007;69:681-698.
- b) Isaias IU, Alterman R and **Tagliati M**. Outcome Predictors for DBS in Primary Dystonia: The Role of Disease Duration. *Brain* 2008;131:1895-902.
- c) Isaias IU, Volkmann J, Kupsch A, Burgunder JM, Ostrem J, Alterman R, Mehdorn HM, Schönecker T, Krauss JK, Starr P, Reese R, Kühn AA, Shupbach M and **Tagliati M**. Long-Term Outcome Predictors of GPi-DBS for Primary Dystonia. *J Neurol* 2011;258(8):1469-76.
- d) Cheung T, Noecker A, McIntyre C, Alterman RL and **Tagliati M**. Defining a Therapeutic Target for Pallidal Deep Brain Stimulation for Dystonia. *Ann Neurol* 2014 Jul;76(1):22-30.

3. Developed clinical knowledge of DBS in movement disorders, contributing new studies on new devices, long term outcomes, stimulation parameters, referring patterns and special indications.

- a) Isaias IU, Alterman R and **Tagliati M**. Deep Brain Stimulation for Primary Generalized Dystonia: Long-term Outcomes. Arch Neurol 2009;66:465-470.
- b) **Tagliati M**, Martin CE, Alterman R. Lack of Motor Symptoms Progression in Parkinson's Disease Patients with Long-Term Bilateral Subthalamic DBS. Int J Neurosci 2010;120:717-723.
- c) Katz M, Kilbane C, Rosengard J, Alterman R and **Tagliati M**. Referring Patients for Deep Brain Stimulation: An Improving Practice. Arch Neurol 2011;68(8):1027-32.
- d) Panov F, **Tagliati M**, Ozelius L, Gologorsky Y, Cheung T, Avshalumov M, Bressman SB, Saunders-Pullman R, Weisz D and Alterman RL. Pallidal Deep Brain Stimulation for DYT-6 Dystonia. J Neurol Neurosurg Psychiat 2012;83(2):182-7. [[.pdf](#)]
- e) Okun MS, Gallo BV, Mandybur G, Jagid J, Foote K, Revilla F, Alterman R, Jankovic J, Simpson R, Junn F, Verhagen L, Arle J, Ford B, Stewart M, Horn S, Baltuch G, Kopell B, Marshall B, Peichel D, Pahwa R, Lyons K, Tröster AI, Vitek J and **Tagliati M**. A Randomized, Controlled Trial of Constant Current Subthalamic DBS in Parkinson's Disease. Lancet Neurology 2012;11(2):140-149.
- f) Cheung T, Nuno M, Hoffman M, Katz M, Killbane C, Alterman RL and **Tagliati M**. Longitudinal impedance variability in patients with chronically implanted DBS devices. Brain Stimulation 2013 Sep;6(5):746-51.

Complete List of Published Work in MyBibliography:

<http://www.ncbi.nlm.nih.gov/pubmed?holding=&cmd=search&term=tagliati+m>

D. RESEARCH SUPPORT

Ongoing Research Support

1. INTREPID Study: Implantable Neurostimulator for the Treatment of Parkinson's disease.
Role: PI
Sponsor Boston Scientific.
Approval dates: 4/15/13 – 3/31/16.
2. KW6002-014 - A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/day as Treatment for Subjects with Moderate to Severe Parkinson's Disease.
Role: PI
Sponsor: KKP Kyowa Kirin Pharma.
Approval dates: 1/15/14 – 1/15/16
3. Deep Brain Stimulation Influence on Autonomic Ocular Functions and Oculomotor Abnormalities in Patients with Advanced Parkinson's Disease – A pilot trial.”
Sponsor: Department of Neurology, CSMC
Approval dates: 9/1/14-8/31/15 (IRB Protocol # 00036808)
4. GE-001-011. A Retrospective Study to Compare the Rates of Agreement Between Clinical Diagnosis and Visual Assessment of DaTscan Images in non-Caucasian and Caucasian Subjects with Parkinson's Disease or Essential Tremor.
PI: A.Waxman
Sponsor: General Electric
Approval dates: pending. Effort 1.5%
5. What is the PKG Fluctuation Score (FS) that distinguishes non-fluctuators and fluctuators in Parkinson's Disease?
Sponsor: Global Kinetics
Approval dates: pending.

6. A Phase II, randomized, double-blinded, placebo-controlled study to evaluate the efficacy of liraglutide in the treatment of people with Parkinson's disease and insulin resistance
Sponsor: The Parkinson UK Trust
Approval dates: pending.

Completed

1. Low Frequency Deep Brain Stimulation for Gait Dysfunction in Parkinson's Disease.
Principal Investigator: M.Tagliati.
Sponsor: The Parkinson Alliance.
Approval dates: 9/24/08-9/23/08. Effort 5%.
2. The MOST Study: Mood and STN DBS. (PI: Michael Okun, MD).
MSSM PI: M.Tagliati.
Sponsor: National Parkinson Foundation.
Approval dates: 1/1/06-12/31/09. Effort 5%.
3. Deep Brain Stimulation Therapy for Movement Disorders: A Study of Long-Term Outcomes And Complications.
Principal Investigator: M.Tagliati.
Sponsor: Bachmann-Strauss Foundation.
Approval dates: 4/24/07-4/23/09. Effort 5%.
4. The Effects of STN-DBS Frequency Changes on Speech In Advanced Parkinson's Disease.
Principal Investigator: M.Tagliati.
Sponsor: Bachmann-Strauss Foundation.
Approval dates: 1/1/09-12/31/09. Effort 5%.
5. Cortical-subcortical interaction in PD and normal speech (PI: John J. Sidtis, PhD)
MSSM PI: M.Tagliati.
Sponsor NIH.
Approval dates: 4/01/06-3/31/011. Effort 5%.
6. Parkinson Center of Excellence Award
Principal Investigator: M.Tagliati
Sponsor: National Parkinson Foundation
Approval dates: 7/1/2009-6/30/2011
7. Analysis of Impedance Variations in a Large Population of Patients with Parkinson's Disease Treated with DBS.
Sponsor: The Parkinson Alliance.
Approval dates: 10/15/11-10/14/12. Effort 5%.
8. A Phase II, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Investigate the Efficacy, Safety, and Tolerability of Cogane (PYM50028), in Subjects with Early-Stage Parkinson's Disease.
Role: Principal Investigator. Sponsor Phytopharm.
Approval dates: 11/15/11-10/31/12.
9. SYN115 as Adjunctive Therapy in Levodopa-Treated Parkinson's Subjects
Role: Principal Investigator. Sponsor Biotie-Synosia.
Approval dates: 12/20/11-11/30/12.
10. Exploring DBS Mechanisms of Action for PD and Dystonia Utilizing Advanced Neuroimaging Techniques
Sponsor: Clinical and Translational Science Institute (CTSI)
Approval dates: 4/1/13-12/31/13.